Multiple Transplantation of Bone Marrow Derived CD133 Cell in Cerebral Palsy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01763255|
Recruitment Status : Completed
First Posted : January 8, 2013
Last Update Posted : April 25, 2014
Cerebral palsy (CP) is condition, sometimes thought of as a group of disorders that can involve brain and nervous system functions such as movement, learning, hearing, seeing, and thinking.Cerebral palsy is caused by injuries or abnormalities of the brain. Most of these problems occur as the baby grows in the womb, but they can happen at any time during the first 2 years of life, while the baby's brain is still developing.Bone marrow derived stem cells are known as a effective therapy.
In this study the investigators evaluate the side effect of multiple intrathecal injection of bone marrow stem cell in patients with cerebral palsy.
|Condition or disease||Intervention/treatment||Phase|
|Cerebral Palsy||Biological: stem cell intrathecal injection||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||8 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Safety of Multiple Intrathecal Injection of Bone Marrow Derived CD133 Cells in Patients With Cerebral Palsy|
|Study Start Date :||April 2012|
|Actual Primary Completion Date :||April 2014|
|Actual Study Completion Date :||April 2014|
Experimental: CD133 transplantation
The patients with cerebral palsy that underwent CD133 transplantation.
Biological: stem cell intrathecal injection
Intrathecal injection of Bone marrow derived CD133 cells
Other Name: Stem cell transplantation
No Intervention: Control
The patients with cerebral palsy that underwent regular observation.
- motor dysfunction [ Time Frame: 6months ]Evaluation the motor dysfunction 6months after intrathecal injection.
- sensory dysfunction [ Time Frame: 6months ]Evaluation the sensory dysfunction after intrathecal injection of CD133 cells.
- unconsciousness [ Time Frame: 48hours ]Evaluation the rate of unconsciousness during 48hours after cell transplantation.
- fever [ Time Frame: 48hours ]Evaluation the symptom of infection like fever 48hours after cell transplantation.
- motor improvement [ Time Frame: 6months ]Measure the improvement of motor system by GMFM66.
- Balance improvement [ Time Frame: 6months ]Measure the balance improvement by BBS.
- Spasm [ Time Frame: 6months ]Evaluation the improvement of spasm after stem cell transplantation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01763255
|Iran, Islamic Republic of|
|Tehran, Iran, Islamic Republic of|
|Study Chair:||Hamid Gourabi, PhD||Head of Royan Institute|
|Study Director:||Nasser Aghdami, MD,PhD||Head of Royan department of degenerative medicine,Head of Royan celltherapy center|
|Study Director:||Ali Reza Zali, MD||Head of Neurosurgery research center of Shahid Beheshti University|